Explain How Seebri and Utibron Stack Up Against Other Inhalers for COPD

February 2016

Two new glycopyrrolate-containing bronchodilators, Seebri (SEE-bree) and Utibron (YOO-tee-bron) Neohalers, will jostle for a place in the COPD market.

Consider these inhalers as me-too drugs.

Think of the single-agent glycopyrrolate (Seebri) as similar to tiotropium (Spiriva), aclidinium (Tudorza), or umeclidinium (Incruse)...and the indacaterol/glycopyrrolate combo (Utibron) as similar to umeclidinium/vilanterol (Anoro) or tiotropium/olodaterol (Stiolto).

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote